ARS Pharmaceuticals, Inc. (SPRY)
NasdaqGM · USD · Healthcare · Biotechnology
$3.92 (-2.73%) as of
Key statistics
- Market cap
- 389.83M
- Forward P/E
- -4.37
- EPS (TTM)
- -2.1200
- Dividend yield
- 0.00%
- 52-week range
- 3.8100 – 13.1500
- Beta
- 1.08
- Revenue (TTM)
- 116.93M
- Profit margin
- -184.24%
- Analyst target
- $24.33
- Volume
- 1.43M
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA, United States
- Employees
- 195
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.